IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
WESTBROOK, Maine, August 31, 2026--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, from 10:45 am – 11:20 am (ET).
Yahoo3 gün önceIDXX
Are Wall Street Analysts Predicting IDEXX Laboratories Stock Will Climb or Sink?
IDEXX Laboratories has struggled to keep pace with the broader market over the past year, but Wall Street still sees plenty of room for the stock to recover, with analysts maintaining a moderately bullish outlook on its prospects.
Yahoo9 gün önceIDXX
Insider Decision: Andrew Emerson Exercises Options At IDEXX Laboratories For $101K
In a new SEC filing on August 24, it was revealed that Emerson, EVP at IDEXX Laboratories (NASDAQ:IDXX), executed a significant exercise of company stock options. What Happened: A Form 4 filing with the U.S. Securities
Benzinga10 gün önceIDXX
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Yahoo14 gün önceIDXX
Rationale Behind Baron Focused Growth Fund’s IDEXX Laboratories (IDXX) Holding
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Focused Growth Fund”. A copy of the letter can be downloaded here. In the second quarter, the Baron Focused Growth Fund achieved a 13.26% gain, still trailing the Russell 2500 Growth Index’s 24.02% return. The underperformance was driven by ongoing concerns […]
Yahoo15 gün önceIDXX
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
Yahoo15 gün önceIDXX
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Yahoo16 gün önceIDXX
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day August 13, 2026 8:00 AM EDTCompany ParticipantsMichael Erickson - CEO, President & DirectorJulie...
SeekingAlpha16 gün önceIDXX
IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution
SeekingAlpha17 gün önceIDXX
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests
IDEXX Laboratories (NASDAQ:IDXX) outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to incre
Yahoo20 gün önceIDXX
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
2026-08-14. The following slide deck was published by IDEXX Laboratories, Inc.
SeekingAlpha21 gün önceIDXX
Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?
IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected veterinary diagnostics portfolio and tapping into an underassessed companion-animal heart disease market. We’ll now examine how the new Catalyst proBNP Test and...
Yahoo22 gün önceIDXX
IDEXX (IDXX) Q2 2026 Earnings Call Transcript
Diagnostic innovations fuel 10% CAG recurring revenue growth despite wellness visit pressure.
Yahoo24 gün önceIDXX
IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
WESTBROOK, Maine, August 11, 2026--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.
Yahoo24 gün önceIDXX
Barclays Maintains Overweight on IDEXX Laboratories, Lowers Price Target to $710
Barclays analyst Glen Santangelo maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from $800 to $710.
Benzinga24 gün önceIDXX
IDEXX Laboratories: Worth The Premium
IDEXX Labs remains a buy: durable moat, recurring revenue, raised FY26 EPS outlook, and long-term international growth. Click to see Q2 highlights & valuation.
SeekingAlpha27 gün önceIDXX
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Yahoo29 gün önceIDXX
UBS Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670
UBS analyst Andrea Alfonso maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $620 to $670.
Benzingageçen ayIDXX
Citigroup Maintains Neutral on IDEXX Laboratories, Raises Price Target to $670
Citigroup analyst Daniel Grosslight maintains IDEXX Laboratories (NASDAQ:IDXX) with a Neutral and raises the price target from $650 to $670.
Benzingageçen ayIDXX